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RESEARCH ARTICLE
CDK-dependent phosphorylation of PHD1 on serine 130 alters its
substrate preference in cells
Brian Ortmann, Dalila Bensaddek, Sara Carvalhal, Sandra C. Moser, Sharon Mudie, Eric R. Griffis,
Jason R. Swedlow, Angus I. Lamond and Sonia Rocha*
ABSTRACT
PHD1 (also known as EGLN2) belongs to a family of prolyl
hydroxylases (PHDs) that are involved in the control of the cellular
response to hypoxia. PHD1 is also able to regulate mitotic
progression through the regulation of the crucial centrosomal
protein Cep192, establishing a link between the oxygen-sensing
and the cell cycle machinery. Here, we demonstrate that PHD1 is
phosphorylated by CDK2, CDK4 and CDK6 at S130. This
phosphorylation fluctuates with the cell cycle and can be induced
through oncogenic activation. Functionally, PHD1 phosphorylation
leads to increased induction of hypoxia-inducible factor (HIF) protein
levels and activity during hypoxia. PHD1 phosphorylation does not
alter its intrinsic enzymatic activity, but instead decreases the
interaction between PHD1 and HIF1α. Interestingly, although
phosphorylation of PHD1 at S130 lowers its activity towards HIF1α,
this modification increases the activity of PHD1 towards Cep192.
These results establish a mechanism by which cell cycle mediators,
such as CDKs, temporally control the activity of PHD1, directly
altering the regulation of HIF1α and Cep192.
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INTRODUCTION
Decreased oxygen levels, or hypoxia, present a major stress to the
cell. Many of the crucial cellular processes, such as ATP production
through oxidative phosphorylation, cell division and cell cycle
progression are all highly energy-demanding processes that require
oxygen (Ortmann et al., 2014). Exposure to hypoxia activates a
number of different responses at both the cellular and whole
organism level. One of the crucial alterations mediated by hypoxia
is a change in gene expression (Kenneth and Rocha, 2008).
Hypoxia activates a variety of transcription factors (Kenneth and
Rocha, 2008), but the most important for survival and adaptation to
this stress is a group of transcription factors known as the hypoxia-
inducible factors (HIFs). These are heterodimeric transcription
factors that comprise an oxygen-labile HIFα subunit and the
constitutively expressed HIF1β subunit (also known as ARNT)
(Moniz et al., 2014). Three different genes encode for the currently
known isoforms of the HIFα subunit [HIF1α, HIF2a (also known as
EPAS1) and HIF3α]. All of the three HIFα isoforms share some
structural similarity, most notably they all contain a basic helix-
loop-helix Per-Arnt-Sim (bHLH-PAS) domain, which is crucial for
its interaction with its transcriptional partner HIF1β (To et al., 2006).
In addition, they also contain an oxygen-dependent degradation
domain (ODD), which renders these proteins sensitive to
proteosomal degradation in the presence of oxygen. Although
transcription and translation of the HIFα isoforms plays a role in the
control of these transcription factors (Bernardi et al., 2006; Nayak
et al., 2013; van Uden et al., 2008, 2011), the oxygen-dependent
control of HIFα is achieved through protein degradation, which
occurs very rapidly in the presence of oxygen (Fandrey et al., 2006).
During normoxia, when cells have access to oxygen, HIFα is
hydroxylated on two key proline residues located within the ODD
domain by a group of proline hydroxylase enzymes (PHDs). PHDs
require molecular oxygen as a co-substrate to carry out
hydroxylation, but they also have a requirement for α-ketoglutarate
(α-KG) and Fe2+ as cofactors (Fandrey et al., 2006). Asα-KG is a key
component of the Krebs cycle, it is thought that, in addition to
sensing oxygen levels, PHDs can also sense the metabolic state
within the cell (Kaelin, 2012). More recent data have shown that the
PHDs are also important for amino acid sensing (Durán et al., 2013).
Currently there are three known isoforms in mammalian cells
(PHD1, PHD2 and PHD3, also known as EGLN2, EGLN1 and
EGLN3, respectively), all of which have the ability to hydroxylate
HIFs. HIF1α is hydroxylated on P402 and P564, whereas HIF2α is
hydroxylated on P405 and P531. Biochemical analysis of all three
isoforms has shown that PHD2 has the highest affinity for HIFs, but,
interestingly, the PHDs also possess preferential affinities for the
proline that they target (Appelhoff et al., 2004; Berra et al., 2003).
Genetic studies have shown that, out of the three isoforms, deletion of
PHD2 is embryonic lethal (Takeda et al., 2006), whereas deletion of
PHD1 and PHD3 are not. However, loss of PHD1 and/or PHD3 lead
to developmental defects, most notably in the cardiovascular system
(Fong and Takeda, 2008; Takeda et al., 2008).
During normoxia, hydroxylation of HIFα creates a binding site
for the von Hippel-Lindau (VHL) tumor suppressor E3 ligase
complex. Binding of VHL results in polyubiquitylation and
proteosomal degradation of HIFα. During hypoxia, when oxygen
levels are decreased, PHD activity is reduced, leading to
stabilization of HIFα and dimerization with HIF1β, resulting in a
transcriptionally active complex. HIFs have been shown to regulate
a large number of genes involved in a variety of cellular processes,
such as metabolism, apoptosis, autophagy, angiogenesis and cell
proliferation (Moniz et al., 2014; Rocha, 2007). The response
engaged during hypoxia promotes cell survival and turns off highly
energy-consuming processes, such as cell proliferation and
translation.
One of the most energy-consuming processes within the cell is
the cell cycle and, hence, cell division. This process must be tightly
regulated to ensure there is no hyperproliferation and/or mis-
segregation of genetic information. Errors within the cell cycle canReceived 2 September 2015; Accepted 18 November 2015
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ultimately lead to disease states, such as cancer. Cell cycle control is
achieved through multiple mechanisms, but amongst the most
important regulators are cyclin-dependent kinases (CDKs) (Besson
et al., 2008; Bloom and Cross, 2007; Obaya and Sedivy, 2002).
CDKs are a family of serine/threonine kinases, which are activated
when the cell chooses to enter the cell cycle. Their activation is
dependent on multiple factors, but most important is their
interaction with their regulatory cyclins (Bloom and Cross, 2007).
In addition, CDK activity is also regulated through their interaction
with inhibitory proteins, such as p21 (also known as CDKN1A) and
p27 (also known as CDKN1B). These proteins interact directly with
the CDKs and inhibit the interaction with their regulatory cyclin
(Besson et al., 2008).
Several studies have shown that hypoxia also affects the cell
cycle. Early work has demonstrated that, upon exposure to hypoxia,
cells are reversibly arrested in G1 or S phase (Gardner et al., 2001;
Ortmann et al., 2014). The mechanisms controlling this arrest have
been shown to be both HIF dependent and independent (Ortmann
et al., 2014). More recent studies have shown that HIF1α can inhibit
DNA replication independently of its transcriptional activity (Hubbi
et al., 2013).
In more recent years, the roles of the PHDs in processes other than
hypoxia have become more apparent. Recently PHD1 has been
shown to regulate the transcription factor FOXO3A (Zheng et al.,
2014). PHD3 has also been shown to hydroxylate PKM2 and
HCLK2 (Luo et al., 2011; Xie et al., 2012). Moreover, our recent
work has shown that PHD1 can regulate mitotic progression through
its ability to control the levels of the key centrosomal component
Cep192 (Moser et al., 2013). However, the mechanism that
determines whether PHD1 targets Cep192, HIFα, or both, is not
known. In addition, there is no information on how these enzymes
engage with the cell cycle.
Here, we show that PHD1 is regulated by the cell cycle at the
post-translational level. We show that PHD1 is phosphorylated at
S130 in a CDK-dependent manner. PHD1 phosphorylation reduces
its interaction with HIF1α, but increases the association between
PHD1 with Cep192. Functionally, this results in increased levels of
HIF1α protein and increased transcriptional activity in response to
hypoxia, and in reduced levels of Cep192 protein. These results
indicate that the behaviour of PHD1 towards different substrates can
be altered by specific post-translational modifications.
RESULTS
PHD1 is phosphorylated on S130
We performed mass spectrometry analysis to map PHD1
phosphorylation events by using extracts from U2OS cells
expressing GFP-tagged PHD1. PHD1–GFP was immunoprecipitated
from cells and then subjected to mass spectrometry analysis
(Fig. 1A, Table 1). A good coverage of PHD1 peptides was
obtained, and we found that S130 was phosphorylated in interphase
cells (Fig. 1A). Mass spectrometry validation was achieved using
antibodies that specifically recognise phosphorylated (phospho-)
serine or threonine residues (Fig. 1B), confirming that PHD1 can be
phosphorylated on serine residues but not on threonine residues
(Fig. 1B). Sequence alignment of PHD1 from different organisms
demonstrates that the S130 phosphorylation site in humans is highly
conserved in higher mammals, mice and rats but is absent in
organisms such as zebrafish, Xenopus and the fruit fly (Fig. 1C). An
antibody against a synthetic phospho-peptide corresponding to the
region around S130 was generated. Antibody specificity and
validation was performed using U2OS cell lines stably expressing
GFP, PHD1–GFP and two GFP-tagged PHD1 mutants cell lines
where the S130 residue has been replaced with either an alanine
(PHD1-S130A) or an aspartate (PHD1-S130D). All of these cells
expressed PHD1 to similar levels (Fig. S1A). Immunoprecipitation
of GFP from the GFP, PHD1–GFP, PHD1-S130A–GFP or PHD1-
S130D–GFP cells, revealed that the phospho-specific antibody only
detected a band in the extracts derived from wild-type PHD1,
demonstrating its specificity (Fig. 1D). In addition, we knocked
down PHD1 levels using several different small interfering RNA
(siRNA) oligonucleotides directed against PHD1, and used the
antibody to determine its specificity in cell extracts (Fig. 1E). A
substantial loss of signal was detected specifically when PHD1 was
depleted, further demonstrating the specificity of this antibody
(Fig. 1E).
Although, endogenous PHD1 levels are difficult to detect in cell
lines other than breast cancer lines (Moser et al., 2013; Zheng et al.,
2014), we used an immunofluorescence approach in U2OS cells to
determine whether the antibody against phospho-S130 PHD1 was
able to detect endogenous protein (Fig. 1F). PHD1 phosphorylation
was localised primarily within the nucleus, consistent with previous
data showing that PHD1 is a nuclear protein (Metzen et al., 2003).
The PHD1 phosphorylation signal was lost when cells were treated
with a PHD1-specific siRNA. The same localisation pattern was also
observed in PHD1–GFP cells (Fig. S1B). Collectively, these results
show that PHD1 is subject to phosphorylation on S130 in cells.
PHD1 phosphorylation is regulated by interphase CDKs
Further analysis of the sequence surrounding the phosphorylation site
revealed it falls into a consensus for CDK phosphorylation [S/T]Px
[R/K] (Endicott et al., 1999). To investigate whether CDKs can
modify PHD1,we determinedwhether PHD1 could be detected by an
antibody specifically directed towards phospho-CDK substrates.
PHD1–GFP was immunoprecipitated from cells, and extracts were
probed with both the antibody for the CDK substrates and with an
anti-PHD1 antibody (Fig. 2A). This revealed that a small proportion
of PHD1 was indeed recognised by the anti-CDK-substrate antibody,
highlighting the potential for PHD1 to be a CDK substrate. In
addition, PHD1 could interact with CDK2, CDK4 and CDK6, but not
CDK1 in cells (Fig. 2B; Fig. S1C).We could also detect an interaction
between PHD1 and CDK2 at the endogenous level (Fig. 2C).
Functionally, depletion of CDK2, CDK4 and CDK6, either
individually or in combination, resulted in reduced levels of
phospho-S130 PHD1 (Fig. 2D,E). CDK1 depletion led to increased
levels of this phosphorylation on PHD1 (Fig. 2D), with a
corresponding increase in cells arrested in the G2 and M phase of
the cell cycle. However, CDK depletion did not alter PHD1
localisation in cells (Fig. S1D). By contrast, gain-of-function
experiments revealed that when increased levels of CDK4 were
present, there was a concomitant increase in the levels of S130
phosphorylation of PHD1 (Fig. 2F), indicating that indeed CDKs
can change the PHD1 phosphorylation status.
To demonstrate that CDKs can phosphorylate PHD1, we also
performed in vitro kinase assays with CDK2 and CDK1 (Fig. 2G,
Fig. S1E). CDK2 was immunoprecipitated from cells, and kinase
assays were performed using bacterially expressed recombinant
PHD1, followed by western blot analysis using the anti-phospho-
PHD1 antibody (Fig. 2G). This analysis showed that CDK2
phosphorylates PHD1 at S130. Interestingly, when a radioactive
kinase assay was performed with recombinant CDK1–cyclin-B, a
CDK for which wewere unable to detect an interaction with PHD1,
we could detect phosphorylation of PHD1 in vitro (Fig. S1E). In
this case, mutation of S130 only slightly reduced the
phosphorylation signal, suggesting that other sites on PHD1 are
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being targeted by CDK1 in vitro. Taken together, these results
suggest that no single CDK is exclusively responsible for the
phosphorylation of PHD1, indicating a redundancy between them.
This is to be expected, as genetic studies have shown that only
CDK1 is essential, as knockout of CDK1 results in significant
developmental defects in mice (Diril et al., 2012).
Fig. 1. See next page for legend.
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S130 phosphorylation of PHD1 is regulated by the cell cycle
and upregulated by oncogenes
Given that our results suggest that S130 phosphorylation is
modulated by several CDKs, we hypothesised that this
phosphorylation might be regulated by the cell cycle. Double-
thymidine block followed by release over a 14-h period revealed that
it was possible to detect S130 phosphorylation of PHD1 throughout
the cell cycle. However, phosphorylation levels peaked during late S
phase and G2 before decreasing again as the cell entered G1
(Fig. 3A). These results indicate that PHD1 phosphorylation is a
cell-cycle-regulated event.
Growth factors are known to be one of the primary drivers for cell
cycle progression, so we first tested whether S130 phosphorylation
was regulated by growth factor stimulation (Fig. 3B). After starving
the cells for 24 h, S130 phosphorylation was decreased when
compared with the control, and this was coupled with an increase in
the percentage of cells in the G1 phase of the cell cycle (Fig. 3B).
Following release, there was a gradual increase in PHD1
phosphorylation, which coincided with an increase of cells
moving into S and G2 phases of the cell cycle. Interestingly, this
increase was delayed when compared with ERK1 and ERK2
(ERK1/2, also known as MAPK3 and MAPK1, respectively)
phosphorylation, indicating that the kinase responsible is activated
later than the ERK pathway.
A primary driver of cell proliferation and cell cycle progression in
the context of cancer is the activation of oncogenes (Matsumura
et al., 2003). We overexpressed the oncogene Myc and two mutant
derivatives. One of the mutants contains a deletion in theMyc box II
domain (ΔMBII), which prevents full transactivation of Myc
(Cowling and Cole, 2008). The other mutant has a T58A mutation
and acts as a Myc gain-of-function mutant (Welcker et al., 2004).
T58 is a known GSK3 phosphorylation site and, without this site,
Myc has increased stability, making it more active (Welcker et al.,
2004). We also tested the effects of overexpression of E2F1 and Src.
Overexpression of either wild-type Myc or either of the mutants, led
to an increase in PHD1 phosphorylation, although the increase in
PHD1 phosphorylation when overexpressing ΔMBII was not very
pronounced (Fig. 3C, lanes 2–4). PHD1 phosphorylation also
increased when E2F1 was overexpressed (Fig. 3C, lane 5), but not
when we overexpressed Src (Fig. 3C, lane 6). This shows that S130
phosphorylation of PHD1 can be induced by increased levels of
oncogenes, such as Myc and E2F1.
PHD1 phosphorylation regulates HIFα levels and activity
As PHD1 is a proline hydroxylase, we next determined whether
phosphorylation of PHD1 at S130 could impact on its intrinsic
enzymatic activity. Previous work performed in bacteria has shown
that PHD1 is potentially phosphorylated on S132 (Li et al., 2008)
and this can lead to a decrease in PHD1 activity in vitro. To analyse
PHD1 activity we used an in vitro hydroxylation assay, using a
peptide derived from the HIF1α ODD sequence, followed by mass
spectrometry (Fig. 4A). This analysis revealed that all the mutants
had similar activity to the wild-type enzyme in vitro. We also
Table 1. Fragmentation ions for phosphorylation of PHD1
b-H3PO4 b-H3PO4+2 b b+2 Sequence y y+2 y+3 y-H3PO4 y-H3PO4+2
– – – – 1 W 18 – – – –
– – 258.1237 – 2 A 17 1876.8338 938.9205 626.2828 1778.8569 889.9321
– – 387.1663 – 3 E 16 1805.7967 903.402 602.6037 1707.8198 854.4135
– – 502.1932 – 4 D 15 1676.7541 838.8807 559.5895 1578.7772 789.8922
– – 559.2147 – 5 G 14 1561.7271 781.3672 521.2472 1463.7502 732.3787
– – 616.2362 – 6 G 13 1504.7057 752.8565 502.2401 1406.7288 703.868
– – 731.2631 – 7 D 12 1447.6842 724.3457 483.2329 1349.7073 675.3573
– – 802.3002 – 8 A 11 1332.6572 666.8323 444.8906 1234.6804 617.8438
– – 899.353 – 9 P 10 1261.6201 631.3137 421.2116 1163.6432 582.3253
968.3745 – 1066.3513 – 10 S(phospho) 9 1164.5674 582.7873 388.8606 1066.5905 533.7989
1065.4272 – 1163.4041 – 11 P 8 997.569 499.2881 333.1945 – –
1152.4592 – 1250.4361 – 12 S 7 900.5162 450.7618 300.8436 – –
1280.5542 640.7807 1378.5311 689.7692 13 K 6 813.4842 407.2457 271.8329 – –
1436.6553 718.8313 1534.6322 767.8197 14 R 5 685.3893 343.1983 229.1346 – –
1533.7081 767.3577 1631.685 816.3461 15 P 4 529.2881 265.1477 – – –
1719.7874 860.3973 1817.7643 909.3858 16 W 3 432.2354 216.6213 – – –
1790.8245 895.9159 1888.8014 944.9043 17 A 2 246.1561 123.5817 – – –
– – – – 18 R 1 175.119 88.0631 – – –
Summary of the theoretical fragment ions generated upon CID fragmentation of the triply charged peptide WAEDGGDAPS(phospho)PSKRPWAR derived from
the tryptic digestion of PHD1. Fragment ions that were observed in our analysis are highlighted in bold (for y ions) and italics for b ions.
Fig. 1. PHD1 is phosphorylated at S130. (A) LC-MS analysis of in-gel-
digested PHD1 allowed the identification of PHD1 (UniProt Q96KS0) with
74.2% sequence coverage (searched against the UniProt human proteome
database). The phosphorylated serine is denoted in red. ES-FTMS product ion
spectrum of the triply charged ion atm/z value 688.3092, which corresponds to
the tryptic peptide WAEDGGDAPS(phospho)PSKRPWAR. An almost
complete y ion series allowed the unambiguous assignment of
phosphorylation to S130 of PHD1. Higher y ions (from y9 to y17) are observed
both with a phosphate group and with a loss of H3PO4. (B) 300 µg of U2OS
GFP and PHD1–GFP cell extracts were subjected to immunoprecipitation (IP)
using GFP-trap beads, and precipitated material was analysed by western
blotting using the indicated antibodies. (C) Sequence alignment diagram for
the PHD1 S130 site within different organisms. The box indicates conserved
SP residues. (D) 300 µg of U2OS GFP, PHD1–GFP, PHD1-S130A–GFP and
PHD1-S130D–GFP cell extracts were subjected to immunoprecipitation using
GFP-trap beads, and precipitated material was analysed by western blotting
using the indicated antibodies. (E) U2OS PHD1–GFP cells were transfected
with control or several PHD1 siRNA oligonucleotides (denoted A, B, C and
UTR) for 48 h prior to lysis. Whole-cell lysates were analysed by western
blotting using the depicted antibodies. UTR, untranslated region. (F) U2OS
cells were transfected with control or PHD1 siRNA (siPHD1) oligonucleotides
for 48 h prior to fixation with PFA. Cells were stained with anti-phospho-S130
PHD1 and PHD1 antibodies, using DAPI as a marker of chromatin. Scale bar:
10 µm. Images were acquired using a Deltavision microscope, deconvolved
and analysed usingOmero software. Pixel intensities were quantified in Omero
using the region of interest (ROI) tool. Graphs depict mean±s.d. of a minimum
of 31 cells per condition. *P<0.05, **P<0.01, ***P<0.001 compared to control
conditions (Student’s t-test). p, phosphorylated form of the protein or residue.
See also Fig. S1.
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Fig. 2. See next page for legend.
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performed this analysis using dot blot and an anti-HIF1α-
hydroxylation antibody (Fig. S2A). We compared hydroxylation
of the HIF peptide over time using recombinant purified GST–
PHD1, GST–PHD1-S1301A and GST–PHD1-S130D proteins. No
significant difference in hydroxylation activity between the wild-
type PHD1 and the two mutants could be detected (Fig. S2A).
These data indicate that phosphorylation of PHD1 at S130 has little
or no effect on the intrinsic enzymatic activity of PHD1.
To determine whether there is a functional role of PHD1 S130
phosphorylation in the cellular response to hypoxia, we started by
analysing the levels of its targets, that is HIF1α and HIF2α. To this
aim, we utilized the GFP, PHD1–GFP, PHD1-S130A–GFP and
PHD1-S130D–GFPU2OS cells, and assessed their PHD activity by
measuring both the levels of hydroxylated HIF1α and total levels of
HIF1α and HIF2α when their degradation was blocked by a
proteasomal inhibitor (Fig. 4B). Specificity of the anti-hydroxy-
HIF1α antibody was confirmed by analysis of extracts from cells
treated with the PHD inhibitors DFX and DMOG (Fig. S2B). In
addition, endogenous PHD1 was depleted by siRNA and, as
expected, when MG132 was added, we saw an accumulation of
HIF1α in all cell types. However, there were decreased levels
of HIF1α in the PHD1–GFP and PHD1-S130A–GFP cells, whereas
HIF1α levels in PHD1-S130D–GFP cells were similar to the cells
expressing GFP alone (Fig. 4B). Similarly, when we analysed
HIF1α hydroxylation levels, less hydroxylation was detected in
PHD1-S130D–GFP cells when compared with PHD1-S130A–GFP
cells. This result suggests that phosphorylation of PHD1 on S130
does impact on the ability of PHD1 to hydroxylate HIF1α in cells.
Interestingly, mutation of S130 alters the PHD1-mediated
regulation of HIF2α, regardless of mutation to alanine or aspartate
(Fig. 4B). As expected, none of the PHD1 mutations affected the
total levels of HIF1β.
In cells exposed to hypoxia, PHD1 overexpression results in a
reduction of HIF1α levels and its targets as expected (Fig. S2C,D).
Hypoxia does not alter PHD1 phosphorylation at earlier times of
exposure but does result in a significant reduction after 24 h
(Fig. S2E). This is to be expected, as exposure to hypoxia for this
period results in G1 arrest (Ortmann et al., 2014), a stage where
PHD1 S130 phosphorylation is reduced. When all three cell lines
were exposed to hypoxia, we detected an induction of HIF1α in
all of them (Fig. 4C), although to lower levels than control cells
(Fig. S2C,F). However, for the PHD1-overexpressing cells, the
highest induction of HIF1αwas observed in the PHD1-S130D–GFP
cells (Fig. 4C). This highlights that the change in hydroxylation
activity we observed when we treated cells with MG132 (Fig. 4B) is
physiologically relevant. In addition, levels of HIF2α are higher in
both of the PHD1 mutant cell lines, this being particularly evident in
PHD1-S130D–GFP cells (Fig. 4C). Despite being less efficient at
targeting HIF1α, PHD1-S130D–GFP is active, as the levels of
HIF1α in these cells are lower than cells expressing GFP alone (Fig.
S2F), indicating that PHD1 hydroxylase activity is still present when
S130 is phosphorylated.
To understand whether the changes in HIF1α levels observed in
the PHD1-S130D–GFP cells are altering HIF1α transcriptional
activity, we assessed HIF activity by investigating the levels of
several HIF target genes. Levels of HIF1α targets were always
higher in PHD1-S130D–GFP cells when compared with cells
expressing wild-type PHD1. However, additional differences were
also observed for PHD1-S130A–GFP cells when compared with
cells expressing wild-type PHD1, with higher levels of PHD2,
PHD3 and CAIX (also known as CA9) observed in these cells
(Fig. 4D). This could reflect the contribution of HIF2α to the
regulation of certain targets (Elvidge et al., 2006). We also analysed
mRNA levels for BNIP3, CAIX and Glut3 (also known as
SLC2A3), at 24 h following exposure to hypoxia in these cells
(Fig. S2G). These results show that levels of HIF1α targets are
always higher in PHD1-S130D–GFP cells when compared with
cells expressing wild-type PHD1. In this analysis, PHD1-S130A–
GFP activity was comparable to wild-type PHD1, for all the genes
analysed (Fig. S2G).
We have shown that PHD1 S130 phosphorylation is regulated by
the cell cycle. As such, we next determined whether cells where
PHD1 phosphorylation is high would have different levels of
HIF1α. To this end, we synchronised cells with a double-thymidine
block, and then released them into fresh medium containing the
PHD inhibitor DFX, and then visualised HIF1α. We initially
determined whether PHDs were still active under these conditions
by investigating the levels of hydroxylated HIF1α in a time course
of DFX treatment (Fig. S2H). We thus chose a 3-h DFX treatment
because, at this time point, HIF is stabilised but still hydroxylated,
and hence PHD activity changes could still be monitored. When we
investigated HIF1α levels in the different stages of the cell cycle, we
could observe that cells in G1 had lower levels of PHD1 S130
phosphorylation as well as lower HIF1α levels (Fig. 4E). By
contrast, when cells were synchronised in either S, or G2 and M
phase, PHD1 S130 phosphorylation increased and so did HIF1α
levels (Fig. 4E). Taken together, this analysis reveals that both the
phosphorylation-mimicking mutation S130D and increased S130
phosphorylation results in reduced PHD1 activity towards HIF1α,
leading to both increased HIF1α levels and increased activity of this
transcription factor under hypoxia.
PHD1 phosphorylation results in increased HIFα half-life by
reducing PHD1–HIFα interaction
Our analysis so far has revealed that PHD1 phosphorylation does
not alter intrinsic enzymatic activity in vitro but does so in the
context of cells, leading to increased levels of HIF1α levels and
activity. To understand the mechanism behind these differences, we
Fig. 2. PHD1 phosphorylation at S130 is regulated by CDKs. (A) 300 µg of
U2OSGFP or PHD1–GFP cell extracts were subjected to immunoprecipitation
(IP) using GFP-trap beads, and precipitated material was analysed by western
blotting using the indicated antibodies. (B) 300 µg of U2OS GFP or PHD1–
GFP cell extracts were subjected to immunoprecipitation using antibodies
towards CDK4, CDK6 and CDK2, and precipitated material was analysed by
western blotting for the presence of PHD1. (C) 500 µg of U2OS cell extracts
were subjected to immunoprecipitation using an anti-PHD1 antibody
crosslinked to Sepharose beads and processed as in A. (D) U2OSPHD1–GFP
cells were transfected with control, CDK1 or CDK2 siRNA (siCDK)
oligonucleotides alone or in combination for 48 h prior to lysis for western
blotting or fixation for FACS analysis. Cell lysates were analysed for the levels
of phosphorylated PHD1 at S130 and appropriate controls. The middle graph
depicts the mean±s.d. of the quantification of the western blot analysis,
representing a minimum of three independent experiments. The right panel
depicts the corresponding cell cycle profile of cells treated as mentioned
(mean±s.d. of a minimum of three independent experiments). (E) U2OS
PHD1–GFP cells were transfected with control or the indicated CDKs siRNAs
alone or in combination for a period of 48 h prior to being processed and
analysed as in D. (F) U2OS PHD1–GFP cells were transfected with 1 µg of
control or CDK4 expression constructs for 48 h prior to lysis and analysed by
western blotting for the levels of phosphorylated PHD1 at S130 and
appropriate controls. Ev, empty vector control. Graph depicts mean±s.d. of the
quantification of the western blot analysis, from a minimum of three
independent experiments. (G) CDK2 was immunoprecipitated from cells and
used in a kinase assay with 2 µg of recombinant PHD1 and PHD1-S130A
protein. Reactions were analysed by western blotting with the indicated
antibodies. *P<0.05, **P<0.01 and ***P<0.001 compared to control conditions
(Student’s t-test). p, phosphorylated form of the protein. See also Fig. S1.
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started by measuring HIF1α half-life in GFP, PHD1–GFP, PHD1-
S130A–GFP and PHD1-S130D–GFP cells, using a cycloheximide
chase approach (Fig. 5A; Fig. S3A). Cells were incubated under
hypoxia for 4 h prior to treatment with cycloheximide for the
indicated periods of time. We measured p53 levels as a positive
control for the treatment, as it is known to have a high turnover rate
Fig. 3. See next page for legend.
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(Fig. S3A). PHD1 levels were stable throughout the timecourse of
the experiment in all cell lines (Fig. 5A; Fig. S3A). Interestingly,
although PHD1–GFP and PHD1-S130A–GFP cells led to a
substantial decrease in HIF1α half-life when compared with GFP
cells, PHD1-S130D–GFP cells had a slower rate of degradation of
HIF1α (Fig. 5A; Fig. S3A). These results are in agreement with the
increased HIF1α levels observed in PHD1-S130D–GFP cells when
exposed to either MG132 or hypoxia.
To determine the mechanism behind the loss of PHD1 targeting
of HIF1α in PHD1-S130D–GFP cells, we next investigated
whether this modification alters the ability of PHD1 to interact
with HIF1α in cells. To this end, we treated cells with MG132, to
stabilise HIF1α, and immunoprecipitated endogenous HIF1α from
all the PHD1 cell lines. Normal IgG was used as a negative control
for this approach (Fig. 5B). As can be seen in the left panel of
Fig. 5B, there was a substantial immunoprecipitation of HIF1α,
with higher levels of HIF1α recovered from the PHD1-S130D–
GFP cells. However, the amount of interacting PHD1 was reduced
in these cells, when compared with PHD1–GFP cells (Fig. 5B).
Interestingly, a reduction in the interaction between HIF1α and
PHD1 was also visible in PHD1-S130A–GFP cells. We also
analysed this interaction using a transient transfection approach in
HEK293 cells (Fig. S3B), again using MG132 treatment to
stabilise HIF1α prior to immunoprecipitation. In this system, we
could again detect a reduction in the level of PHD1 that interacts
with HIF1α in the cells transfected with the PHD1-S130D–GFP
construct (Fig. S3B). By contrast, there was no difference between
PHD1–GFP- and PHD1-S130A–GFP-transfected cells in the
levels of interaction between PHD1 and HIF1α. These results
suggest that phosphorylation of PHD1 at S130 disrupts the
interaction between HIF1α and PHD1.
We next determined whether the N-terminal region of PHD1 can
bind HIF1α. Different PHD1 deletions were created according to the
domain structure for PHD1 (Fig. 5C) and the subcellular localisation
of these mutants was assessed by fluorescence microscopy. This
revealed that all deletion constructs had a nuclear localisation, with
the exception of the construct containing the hydroxylase domain
only, which was diffusely distributed throughout the cell (Fig. S3C).
This is to be expected, as this construct lacks the nuclear localisation
signal. Furthermore, we could detect good expression levels of all of
the constructs in cells when these were analysed by western blotting
(Fig. S3D). Interaction assays with the deletion constructs revealed
that both the N-terminal and C-terminal regions of PHD1 were able
to interact with HIF1α in cells (Fig. 5D). We also analysed the effect
of a phospho-mimicking mutation on the construct containing the
hydroxylation domain but lacking the first 100 amino acids. Under
these conditions, although the levels of immunoprecipitated HIF1α
were similar for both PHD1 constructs, we observed a reduced
interaction with the PHD1 construct containing the S130Dmutation
(Fig. 5E). These results suggest that the N-terminal region of PHD1,
and in particular S130, is important for PHD1 binding to HIF1α.
PHD1 S130 is important for the control of the cell cycle
We previously identified Cep192 as a new PHD1 target (Moser
et al., 2013). Cep192 is important for cell cycle progression, in
particular for controlling the process of mitosis and spindle
assembly (Joukov et al., 2014; Moser et al., 2013). We next
determined the impact of PHD1 S130 on cell proliferation (Fig. 6A).
In cells depleted of endogenous PHD1 and only expressing GFP,
there was no evident cell proliferation. However, this was restored in
cells expressing exogenous wild-type PHD1 and also in cells
expressing PHD1 with the S130A mutation (Fig. 6A). Interestingly,
PHD1-S130D was unable to restore proliferation in cells depleted of
endogenous PHD1 (Fig. 6A). This suggests that phosphorylation of
S130 in PHD1 alters PHD1 function, either towards Cep192
directly, or to an alternative, as yet unknown, substrate controlling
cell cycle progression.
Given the defects observed in proliferation of cells expressing
PHD1-S130D, we next investigated the levels of Cep192 in all
PHD1 cell lines by performing immunofluorescence studies.
Depletion of PHD1 resulted in an increase in Cep192 levels in
GFP cells (Fig. 6B), as previously published (Moser et al., 2013).
Expression of either wild-type PHD1, or the PHD1-S130A mutant,
restored Cep192 levels to that seen in control siRNA GFP cells
(Fig. 6B). Importantly, in PHD1-S130D–GFP cells, levels of
Cep192 were significantly lower than in either control siRNA-
depleted cells, or in PHD1–GFP and PHD1-S130A–GFP cells,
indicating that the phospho-mimic mutant of PHD1 has increased
activity towards Cep192 in cells (Fig. 6B). As Cep192 is important
for the recruitment of centrosomal components, we also investigated
the levels of pericentrin under the same conditions. Once again,
GFP-expressing cells depleted of PHD1 had higher levels of
pericentrin, as we have previously reported (Moser et al., 2013).
Again, although PHD1 and PHD1-S130A rescued this effect,
expression of PHD1-S130D, did not (Fig. 6B).
Given the reduced levels of Cep192 in PHD1-S130D cells, we
hypothesised that once phosphorylated, PHD1 had enhanced
activity towards Cep192. To investigate this, we analysed whether
PHD1 could interact differently with Cep192 in wild-type versus
PHD1 S130 mutant cells. This analysis revealed that increased
levels of PHD1 were immunoprecipitated with Cep192 in phospho-
mimicking PHD1 cells (Fig. 6C). By contrast, the non-
phosphorylatable mutant PHD1 had a similar ability to interact
with Cep192 as wild-type PHD1 (Fig. 6C). Once again, when we
analysed the activity of recombinant PHD1 wild-type and mutants
in vitro, using a peptide from Cep192 followed by mass
spectrometry analysis, we could not detect any change in PHD1
hydroxylase activity (Fig. S4A), indicating that phosphorylation is
modulating PHD1 activity only in cells, and not affecting PHD1
intrinsic hydroxylase activity.
Fig. 3. PHD1 phosphorylation at S130 is regulated by the cell cycle and
responds to mitogenic signalling. (A) U2OS PHD1–GFP cells were subject
to a double-thymidine block release protocol prior to lysis or fixation after the
indicated periods of time. The left panel depicts western blot analysis for the
levels of phosphorylated PHD1 at S130, and appropriate controls. The right
panel represents the cell cycle profile of matching samples analysed by flow
cytometry. AS, asynchronous. Graph depicts mean±s.d. of a minimum of three
independent experiments. G1, S, and G2/M are the phases of the cell cycle
that correspond to the indicated time points. (B) U2OS PHD1–GFP cells were
serum starved for 24 h prior to addition of full serum medium and were
harvested at the indicated times. Cells were lysed for western blot analysis or
fixed for FACS analysis. Cell lysates were analysed for the levels of
phosphorylated PHD1 at S130, and appropriate controls, where
phosphorylated ERK1/2 was used as a marker of mitogenic signalling. The
right graph depicts the mean±s.d. of the quantification of the western blot
analysis, representing a minimum of three independent experiments. The
bottom panel depicts the corresponding cell cycle profile of cells treated as
mentioned above. The graph depicts the mean±s.d. of a minimum of three
independent experiments. (C) U2OS PHD1–GFP cells were transfected with
1 µg of empty vector (Ev) control or the indicated oncogenes for 48 h prior to
lysis for western blot analysis. Cell lysates were analysed for the levels of
phosphorylated PHD1 at S130 and appropriate controls. The right graph
depicts the mean±s.d. of the quantification of the western blot analysis,
representing a minimum of three independent experiments. *P<0.05, **P<0.01
and ***P<0.001 compared to control conditions (Student’s t-test).
p, phosphorylated form of the protein.
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Fig. 4. See next page for legend.
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To determine whether S130 phosphorylation correlated with
Cep192 levels, we analysed the synchronisation release samples
described in Fig. 3A for the levels of Cep192 (Fig. 6D). There, it
was possible to observe that Cep192 levels were inversely correlated
with PHD1 phosphorylation at S130 and HIF1α levels (Fig. 6D).
Our results suggest that S130 phosphorylation of PHD1 results in
reduced targeting of HIF1α and increased targeting of Cep192 by
this enzyme. We next investigated whether alteration in the levels of
Cep192 resulted in changes to the levels of HIF1α. To this end, we
depleted either Cep192 or the ubiquitin ligase Skp2, which we have
previously shown to regulate Cep192 levels in a manner dependent
on PHD1 (Moser et al., 2013). Reducing the levels of Cep192
resulted in reduced levels of HIF1α. Conversely, in the absence of
Skp2, when more Cep192 was present, higher levels of HIF1α were
observed (Fig. 6E). Skp2 itself is regulated by hypoxia, due to the
fact that cells arrest in G1, and Skp2 levels are regulated by the cell
cycle (Ortmann et al., 2014; Yamada et al., 2013). Similar results
were also observed in cells overexpressing Cep192 (Fig. S4B).
These results suggest that competition between the HIF and Cep192
substrates can occur.
Taken together, we conclude that S130 phosphorylation by
interphase CDKs is an important determinant of which substrate
PHD1 will target in cells (Fig. 6F).
DISCUSSION
In this report, we have identified and characterised the functional
significance of a CDK-dependent phosphorylation site on PHD1.
Our results show that phosphorylation of PHD1 on S130 is dynamic
and regulated by CDK activity, cell cycle stage and oncogenic
signals. Interestingly, although phosphorylation of PHD1 on S130
does not alter PHD1 hydroxylase activity in vitro, it regulates PHD1
activity in cells, determining target selection between HIF and
Cep192. These results provide a mechanistic link between the cell
cycle and the regulation of PHD1 activity in cells, allowing for its
different functions to be carried out at specific stages of the cell
cycle.
Although PHD2 and PHD3 are transcriptional targets of HIF1α
(Metzen et al., 2005; Pescador et al., 2005), PHD1 is not induced
following HIF1α activation. However, the activity of all of these
enzymes is regulated by availability of cofactors, such as molecular
oxygen, Fe2+ and α-KG (Fandrey et al., 2006; Kaelin, 2012). Little
information exists about how PHD protein levels are regulated.
Some studies have demonstrated that PHD3 protein turnover is
regulated by the Siah-2 ubiquitin ligase (Nakayama and Ronai,
2004), whereas the FKBP38 protein, a peptidyl-prolyl cis-trans
isomerase, regulates the protein stability of PHD2 (Barth et al.,
2009, 2007). More recently, PHD3 has been shown to be
sumoylated, which although not altering PHD3 hydroxylase
activity, was important for PHD3-mediated repression of HIF1α
transcriptional activity (Nunez-O’Mara et al., 2015).
Despite these studies, there was no information on how these
processes are regulated and how different signalling pathways and/
or cellular processes integrate with PHD function. Here, we describe
how PHD1 function is regulated by phosphorylation. S130 of PHD1
is well conserved in different mammalian species and, as such, we
would predict that PHD1 could be regulated in a similar manner in
these species. A closely related site is also present on PHD2, where
S125 has been identified as a phosphorylation site in unbiased mass
spectrometry screens (Olsen et al., 2010; Zhou et al., 2013).
Although no functional characterisation has been done for PHD2,
these mass spectrometry screens have suggested that
phosphorylation of PHD2 S125 is also regulated by the cell cycle
(Olsen et al., 2010; Zhou et al., 2013). However, further research on
PHD2 regulation is needed before any conclusion can be made
regarding the importance of this phosphorylation site in cells under
physiological conditions.
Our data suggest that interphase CDKs (CDK2, CDK4 and
CDK6) are involved in the regulation of PHD1 phosphorylation on
S130, but not CDK1. Previous data have indicated that CDKs show
a degree of functional redundancy and can compensate for each
other, with only CDK1 being essential (Diril et al., 2012). Our data
supports this view. In fact, we could detect CDK2, CDK4 and
CDK6 binding to PHD1, but not CDK1, further indicating that
S130 is likely not a CDK1 phosphorylation site in cells. However,
CDK1 was still able to phosphorylate PHD1 in vitro.
Phosphorylation of this site was induced by serum, and by
particular oncogenes, such as Myc and E2F1, both of which are
known to regulate the cell cycle (Matsumura et al., 2003; Obaya
et al., 2002). This strengthens the notion that phosphorylation of
PHD1 at S130 could be of relevance to cancer biology and future
research should be directed to investigate this site in the context of
this disease.
Although PHD2 is the main regulator of HIF1α, PHD1 is also
involved (Appelhoff et al., 2004). Our results show that a phospho-
mimicking mutation of S130 (S130D), reduces PHD1 activity
towards HIF1α, leading to increased HIF1α half-life and activity.
Interestingly, this S130Dmutation did not alter hydroxylase activity
in vitro, when recombinant protein was analysed, but instead altered
the interaction between PHD1 and HIF1α in cells. This could be due
either to inability to bind a cofactor in cells or to a direct interference
of the phosphorylation site with binding to HIF1α. Our analysis
revealed that the N-terminal region of PHD1 is able to bind HIF1α
without the help of the hydroxylation domain, suggesting that this
Fig. 4. PHD1 phosphorylation at S130modulates HIFmediated responses
to hypoxia. (A) Recombinant purified PHD1, PHD1-S130A and PHD1-S130D
enzymes were used in an in vitro hydroxylation assay using a peptide
derived from the HIF1α ODD region (containing proline 564). Reactions were
stopped with the addition of DFX, and samples were analysed by mass
spectrometry. Electrospray-MS spectrum of the product of in vitro
hydroxylation of the HIF1α peptide LDLEMLAPYIPMDDD showing an m/z
increment of 7.99 Th (mass increment of 15.9944 Da) corresponding to proline
hydroxylation of the doubly charged ion atm/z 875.8993 Th and the formation
of the ion 883.8965 Th (themass of the hydroxylated peptide) corresponding to
the hydroxylation of proline 564 of HIF1α. The ion normalized level (NL) for the
hydroxylated peptide is 2.89×107 for wild-type PHD1, 3.92×107 for PHD1-
S130A and 4.06×107 for PHD1-S130D. (B) U2OS GFP, PHD1–GFP, PHD1-
S130A–GFP and PHD1-S130D–GFP were transfected with PHD1 siRNA
targeting the 3′-UTR (untranslated region) of endogenous PHD1 mRNA for
48 h prior to treatment withMG132 for 3 h.Whole-cell lysates were analysed by
western blotting for the levels of the indicated proteins. Graph depicts western
blot quantification showing mean±s.d. of a minimum of three independent
experiments. (C) U2OS PHD1–GFP, PHD1-S130A–GFP and PHD1-S130D–
GFP cells were exposed to 1%O2 for the indicated periods of time prior to lysis.
Whole-cell lysates were analysed by western blotting using the indicated
antibodies. (D) Cell extracts obtained in C were analysed for the levels of the
indicated HIF-dependent targets by western blotting. The graph depicts the
quantification of western blots for HK2 and BNIP3, and illustrates the
mean±s.d. for aminimum of three independent experiments. (E) U2OSPHD1–
GFP cells were subject to a double-thymidine block release protocol prior to
lysis or fixation on the indicated periods of time. For the last 3 h of each time
point, 200 µM DFX was added to the cells. The left panel depicts western blot
analysis for the levels of phosphorylated PHD1 at S130 and appropriate
controls. The right panel represents the cell cycle profile of matching samples
analysed by flow cytometry. AS, asynchronous. The graph depicts mean±s.d.
of a minimum of three independent experiments. *P<0.05, **P<0.01 and
***P<0.001, compared to control conditions or as indicated (Student’s t-test).
See also Fig. S2.
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latter point might be the case. The N-terminus of PHD2 has also
been shown to be important for the regulation of HIF1α by PHD2,
although in this case through an indirect mechanism involving a
chaperone protein (Song et al., 2013). This highlights the fact that
other domains of PHD enzymes can contribute to the hydroxylase
activity of these enzymes in cells.
Fig. 5. PHD1 phosphorylation at Serine 130 alters the ability of PHD1 to target HIF1α. (A) U2OS PHD1–GFP, PHD1-S130A–GFP and PHD1-S130D–GFP
cells were exposed to 1%O2 for 4 h prior to treatment with cycloheximide for the indicated periods of time.Whole-cell lysates were analysed by western blotting for
the levels of HIF1α and appropriate controls. Western blots were quantified and the graph depicts mean±s.d. of a minimum of three independent experiments.
(B) U2OSGFP, PHD1–GFP, PHD1-S130A–GFP and PHD1-S130D–GFP cells were treated with MG132 for 3 h prior to lysis. 300 µg of cell extracts were used to
immunoprecipitate (IP) HIF1α, with normal mouse IgG used as a control. Precipitated material was analysed by western blotting for the indicated proteins.
Western blots were quantified, and the graph depicts the mean±s.d. of a minimum of three independent experiments. (C) Schematic diagram of the PHD1
expression constructs used in this study. Highlighted are the nuclear localization signal (NLS), S130 and the hydroxylase domain (HD). (D) HEK293 cells were
transfected with 1 µg of the indicated expression constructs for 48 h prior to treatment with MG132 and processed as in B. *, non specific band. (E) HEK293 were
transfected with 1 µg of the indicated expression constructs for 48 h prior to treatment with MG132 and processed as in B. Western blots were quantified, and the
graph depicts mean±s.d. of a minimum of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to control conditions (Student’s t-test).
See also Fig. S3.
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Recently, we have identified the centrosomal protein Cep192 as a
target for PHD1 in cells (Moser et al., 2013). Cep192 requires a
precise regulation of its expression level to allow for centrosome
duplication and maturation (Joukov et al., 2014; Moser et al., 2013).
As such, either too much or too little Cep192 results in a similar
defect in centrosomes and causes cell cycle arrest. Given the finding
Fig. 6. See next page for legend.
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presented here concerning the regulation of PHD1 function by
phosphorylation, we investigated how S130 phosphorylation of
PHD1 impinged on cell cycle progression and Cep192 levels. In
rescue experiments, where endogenous PHD1 was depleted,
exogenous expression of either wild-type PHD1 or the
unphosphorylatable S130A PHD1 mutant meant that cells were
able to proliferate, and both proteins restored Cep192 levels.
However, the exogenous expression of the phospho-mimic mutant
S130D was unable to restore proliferation and resulted in reduced
levels of Cep192 when compared with control cells. In addition, we
observed increased interaction between PHD1 and Cep192 in the
phospho-mimic mutant S130D cells. This suggests that PHD1 at
phosphorylated S130 has increased activity towards Cep192,
corroborating the notion that phosphorylation of this site can alter
the target specificity of PHD1. This provides a mechanism by which
PHD1 function could be changed throughout the cell cycle,
directing it towards specific targets in response to signals, such as
high interphase CDK activity, for example.
Taken together, our results suggest a new paradigm for the
regulation of PHD1 function by post-translational modifications.We
have focused on characterising the functional consequences of
PHD1 phosphorylation on S130 due to its conservation across
species, and because of the presence of a similar site on PHD2.
Despite this conservation, the effects of phosphorylation of PHD1 at
S130 will probably only alter HIF levels, as the Cep192
hydroxylation site is not conserved in mice (Moser et al., 2013).
However, additional post-translational modifications might also
occur in these enzymes that help regulate activity and control the
targeting of PHDs to specific substrates in cells. Further investigation
will reveal whether this is the case.
MATERIALS AND METHODS
Cells
U2OS osteosarcoma cancer cells and HEK293 human embryonic kidney
cells were obtained from the European Collection of Cell Cultures and
grown in Dulbecco’s modified Eagle medium (Lonza) supplemented
with 10% fetal bovine serum (Gibco), 50 units/ml penicillin (Lonza) and
50 µg/ml streptomycin (Lonza) for no more than 30 passages at 37°C and
5% CO2. Stable U2OS cell lines expressing GFP, PHD1–GFP, PHD1-
S130A–GFP, and PHD1-S130D–GFP were maintained with 400 µg/ml
G418. U2OS-HRE-luciferase cells were maintained in 0.5 µg/ml
puromycin. Cells were routinely tested for contamination.
Plasmids
GFP-N1 was obtained from Clonetech. GFP–PHD1 was a kind gift from
Eric Metzen (Essen University, Essen, Germany) and was used as a template
to create the GFP-tagged PHD1-S130A and PHD1-S130Dmutations by site
directed mutagenesis. For the truncation mutants of PHD1, GFP–PHD1 and
GFP–PHD1-S130D plasmids were used as templates. Primer sequences are
available upon request.
CMV-HIF1α and CMV-Src expression constructs were obtained from
Origene. E2F1 and wild-type Myc and mutant expression constructs were a
kind gift from Victoria Cowling (University of Dundee, Dundee, UK). HA–
CDK1 (1888, Addgene), HA–CDK4 (1876,Addgene) andHA–CDK2 (1884,
Addgene) were as previously described (van den Heuvel and Harlow, 1993).
Hypoxia induction and chemical treatments
Cells were incubated at 1% O2 in an in vivo 300 hypoxia workstation
(Ruskin, UK). Cells were lysed for protein extracts and RNA extraction in
the work station to avoid re-oxygenation. Whole-cell lysates were obtained
using Triton lysis buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1%
Triton X-100, 250 mM Na3VO4, 10 mM NaF and phosphatase inhibitors 1
tablet, 10 ml (Roche cOmplete)]. RNA was extracted using Peqlab Total
RNA Kit (Peqlab) as per the manufacturer’s instructions.
MG132 was obtained from Merck/Millipore and used at the final
concentration of 20 µM for 3 h. Desferroxamine mesylate (DFX) was
obtained from Sigma and used at the final concentration of 200 µM.
In vitro hydroxylation assay
Hydroxylation assays were performed as in Moser et al. (2013).
Kinase assays
Kinases assays were performed as described in DeGregori et al. (1995). 2 µg
of recombinant PHD1 protein was used per reaction.
Antibodies
Antibodies were against the following proteins: phospho-serine-CDK
substrate (2324, Cell Signaling), 1:1000; phospho-threonine (9386, Cell
Signaling), 1:1000; phospho-serine (05-1000, Millipore), 1:1000; HIF1α
(610958, BDBiosciences and sc-53546 Santa Cruz Biotechnology), 1:1000;
HO-HIF1α (3434, Cell Signaling), 1:1000; HIF-2α (PA1-16510, Thermo
Scientific), 1:1000; HIF-1β (#3718, Cell Signaling), 1:1000; β-actin (3700,
Cell Signaling), 1:5000; CAIX (NB100-417, Novus Biologicals), 1:1000;
HK2 (2867, Cell Signaling), 1:1000; BNIP3 (ab10433, Abcam), 1:2000;
GLUT3 (53520, Anaspec), 1:1000; PHD3 (A300-327A, Bethyl labs),
1:1000; PHD1 (Bethyl A300-326A; Novus NBP1-40773), 1:1000; PHD2
(Bethyl A300-322A), 1:1000; Cep192 (Bethyl A302-324A; Novus NBP-
84634), 1:500; HDAC1 (17-10199, Millipore), 1:2000; CDK1 (9116, Cell
Signaling), 1:1000; CDK2 (2546, Cell Signaling), 1:1000; CDK4 (sc-260,
Santa Cruz Biotechnology; 2906, Cell Signaling), 1:1000; CDK6 (sc-177,
Santa Cruz Biotechnology; 3136, Cell Signaling), 1:1000; phospho-ERK1/2,
1:1000; cyclin A (sc-596, Santa Cruz Biotechnology), 1:1000, cyclin E
(4129, Cell Signaling), 1:1000; E2F1 (3742, Cell Signaling), 1:1000; Src
(2109, Cell Signaling), 1:1000; cMyc (gift from Victoria Cowling), 1:500;
p53 (2524, Cell Signaling), 1:2000; pericentrin (28144, Abcam), 1:100;
phospho-S130-PHD1 [produced in rabbits by immunisation with phospho-
peptide for S130 of PHD1 (CEDGGDAPSphPSKR) and purified by Dundee
Cell products], 1:200.
Immunoprecipitation of PHD1 and sample preparation for LC-MS
analysis
PHD1–GFP cells were lysed as described previously (Moser et al., 2013)
and PHD1 was immunoprecipitated using GFP-TRAP® magnetic beads
(ChromoTek).
Immunoprecipitation eluates were separated on 1D SDS PAGE gels and
stained (SimplyBlue; Invitrogen). The protein bands of interest were
Fig. 6. S130 of PHD1 is important for PHD1-mediated control of cell
proliferation. (A) U2OS GFP, PHD1–GFP, PHD1-S130A–GFP and PHD1-
S130D–GFP cells were transfected with siRNA oligonucleotides targeting the
3′UTR of endogenous PHD1 prior to proliferation being assessed. Total cell
numbers were counted, and the graph depicts mean±s.d. of a minimum of
three independent experiments. Data were normalised to proliferation in GFP
cells and expressed as a percentage. (B) U2OS GFP, PHD1GFP, PHD1-
S130A–GFP and PHD1-S130D–GFP cells were transfected with siRNA
oligonucleotides targeting the 3′UTRof endogenous PHD1 prior to fixation and
immunostaining for Cep192 and pericentrin. Scale bars: 2 µm. Graph depicts
box-and-whisker plots for Cep192 and Pericentrin intensity. Box-and-whisker
plot, middle line shows the median value; the bottom and top of the box show
the lower and upper quartiles (25-75%); whiskers extend to 10th and 90th
percentiles, and all outliers are shown. n=22–38 cells per condition. (C) U2OS
GFP, PHD1GFP, PHD1-S130A–GFP and PHD1-S130D–GFP cells were
treated with MG132 for 3 h prior to lysis. 300 µg of cell extracts were used to
immunoprecipitate (IP) Cep192, with normal mouse IgG used as a control.
Precipitated material was analysed by western blotting for the indicated
proteins. Western blots were quantified and the graph depicts mean±s.d. of a
minimum of three independent experiments. (D) Cell extracts from Fig. 3Awere
analysed by western blotting for the levels of Cep192 and HIF1α. G1, S, and
G2/M are the phases of the cell cycle that correspond to the indicated time
points. (E) U2OS were transfected with the indicated siRNAs prior to treatment
with 1% O2 for 24 h. Whole-cell lysates were analysed by western blotting
using the depicted antibodies. (F) Schematic diagram for the proposed model
for PHD1 regulation by CDKs. *P<0.05, **P<0.01 and ***P<0.001 compared to
control (Student’s t-test). See also Fig. S4.
203
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 191-205 doi:10.1242/jcs.179911
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
excised, chopped into ∼1-mm×1-mm pieces and destained at room
temperature [2×30 min in 50:50, acetonitrile (ACN) and 100 mM
triethylammonium bicarbonate buffer (TEAB) pH 8.5]. After 15 min
dehydration in 100% ACN, proteins in the gel pieces were reduced by
incubation in 25 mM tris(2-carboxyethyl)phosphine (TCEP) in 100 mM
TEAB for 15 min at 37°C and alkylated by adding iodoacetamide to a final
concentration of 50 mM and incubating in the dark at room temperature for
30 min.
After reduction and alkylation, the gel pieces were washed with 50:50
acetonitrile and TEAB to remove excess iodoacetamide, dehydrated in
acetonitrile then dried in a vacuum to remove residual organic solvent prior
to digestion. For tryptic digestion, the dried gel pieces were rehydrated using
sequencing grade modified trypsin (Promega) solution (15 µl, 1 ng µl−1 in
TEAB). Digestion was performed overnight at 37°C in 50 µl TEAB.
Digested peptides were extracted by adding 1% formic acid in acetonitrile
(50 µl) to the gel pieces and incubating for 20 min at room temperature. The
supernatant, now containing tryptic peptides, was transferred to a clean tube.
The gel pieces were extracted further with two washes with 100 µl water:
acetonitrile (50:50) incorporating 1% formic acid and once wash with 100%
ACN. All extracts were combined, dried down and redissolved in 5%
aqueous formic acid for liquid chromatographymass spectrometry (LC-MS)
analysis.
LC-MS analysis
The digests were analysed using a nano-LC (RSLC-Thermo Scientific)
coupled to a Q-exactive orbitrap (Thermo Scientific). The peptides were
loaded in 5% formic acid and resolved on a 50-cm RP-C18 EASY-Spray
temperature-controlled integrated column-emitter (Thermo Scientific)
using a 2-h multistep gradient of acetonitrile (5% acetonitrile to 60%
acetonitrile). The chromatography was performed at a constant
temperature of 40°C. The peptides eluted directly into the sampling
region of the mass spectrometer, and the spray was initiated by applying
1.9 kV to the EASY-Spray (Thermo Scientific). The data were acquired
under the control of Xcalibur software in a data-dependent mode,
selecting the 15 most-intense ions for sequencing by tandem mass
spectrometry using higher-energy collisional dissociation (HCD)
fragmentation. The raw data were processed using the MaxQuant
software package (version 1.3.0.5) (Cox and Mann, 2008) to identify
the proteins enriched in the immuno-affinity pulldowns by searching
against the human proteome database with phosphorylated serine,
threonine and tyrosine as a variable modification, in addition to the
commonly used post-translational modifications (protein N-terminal
acetylation, methionine oxidation, asparagine and glutamine
deamidation, carbamidomethyl cysteine and conversion of N-terminal
glutamate into pyroglutamate).
Additional experimental procedures
siRNA transfection, quantitative real-time PCR (qPCR),
immunofluorescence, synchronisation release and cell cycle analysis
experiments were performed as previously described (Kenneth et al.,
2010; Melvin et al., 2011). Primer and siRNA sequences are available upon
request.
Statistical analysis
P-values were calculated with Student’s t-tests (unless otherwise indicated)
in all the data comparing control to treatment. *P<0.05, **P<0.01 and
***P<0.001.
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